LAVA THERAPEUTICS N.V.

(LVTX)
  Report
Delayed Nasdaq  -  05/20 03:36:06 pm EDT
3.440 USD   +2.38%
05/18SVB Securities Adjusts LAVA Therapeutics' Price Target to $25 From $23, Keeps Outperform Rating
MT
05/17LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
GL
05/17LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

12/20/2021 | 07:01am EDT

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, chief executive officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2021 at 1:30 p.m. EST.

“We are excited to round out a transformative 2021 and eager to kick-off what promises to be an exciting 2022 for LAVA,” said Stephen Hurly, president and chief executive officer. “With both of our lead liquid and solid tumor Gammabody™ programs actively recruiting patients, our focus is on carrying out our mission to rapidly develop new cancer treatments that leverage gamma delta T cells to save patients’ lives.”

Access to the recording will be available under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage biotechnology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the potential treatment of solid tumors and hematological malignancies. The company’s innovative approach utilizes bispecific antibodies engineered to selectively kill cancer cells via the triggering of Vγ9Vδ2 T cell antitumor effector functions upon cross-linking to tumor associated antigens. A Phase 1/2a clinical study evaluating LAVA-051 in patients with certain hematological malignancies is currently enrolling (NCT04887259). The company currently anticipates data from the Phase 1 dose escalation phase of the study in the first half of 2022 with top line clinical data from the Phase 2a expansion cohorts expected in the second half of 2022. The company is actively recruiting patients in a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer. For more information, please visit www.lavatherapeutics.com and follow us on LinkedIn and Twitter.

LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect of the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “will,” “may,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release and are subject to various risks and uncertainties that may cause actual results to differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the preclinical data, clinical development and scope of clinical trials, and the potential use of our product candidates to treat various tumor targets. Many factors, risks and uncertainties may cause differences between current expectations and actual results including, among other things, the timing and results of our research and development programs and preclinical and clinical trials, our ability to obtain regulatory approval for and commercialize our product candidates, our ability to leverage our initial programs to develop additional product candidates using our Gammabody™ platform, and the failure of LAVA’s collaborators to support or advance collaborations or our product candidates. In addition, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT
Edward Smith
Chief Financial Officer
ir@lavatherapeutics.com 

Catherine Day
+1-917-763-2709
catherine@newdaybioconsulting.com


Primary Logo

Source: LAVA Therapeutics N.V.

2021 GlobeNewswire, Inc., source Press Releases

All news about LAVA THERAPEUTICS N.V.
05/18SVB Securities Adjusts LAVA Therapeutics' Price Target to $25 From $23, Keeps Outperfor..
MT
05/17LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
GL
05/17LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
AQ
05/17LAVA Therapeutics N.V. Announces the Resignation of Ed Smith as Chief Financial Officer
CI
05/12Lava Therapeutics Says FDA Clears IND Application for Lava-051 to Treat Leukemia, Other..
MT
05/12LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematol..
GL
05/12LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematol..
AQ
05/12Lava Therapeutics N.V. Announces FDA IND Clearance for Lava-051 for the Treatment of He..
CI
05/05LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
GL
05/05LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
GL
More news
Analyst Recommendations on LAVA THERAPEUTICS N.V.
More recommendations
Financials
Sales 2022 4,00 M 4,22 M 4,22 M
Net income 2022 -58,9 M -62,2 M -62,2 M
Net cash 2022 99,6 M 105 M 105 M
P/E ratio 2022 -1,59x
Yield 2022 -
Capitalization 84,0 M 88,7 M 88,7 M
EV / Sales 2022 -3,89x
EV / Sales 2023 -
Nbr of Employees 57
Free-Float 70,7%
Chart LAVA THERAPEUTICS N.V.
Duration : Period :
LAVA Therapeutics N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LAVA THERAPEUTICS N.V.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,26 €
Average target price 21,15 €
Spread / Average Target 549%
EPS Revisions
Managers and Directors
Stephen Allen Hurly President, Chief Executive Officer & MD
Edward F. Smith Chief Financial Officer
Kapil Dhingra Non-Executive Chairman
Benjamin Winograd Chief Medical Officer
Hans van der Vliet Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
LAVA THERAPEUTICS N.V.-37.45%89
MODERNA, INC.-46.35%54 195
LONZA GROUP AG-27.84%41 796
IQVIA HOLDINGS INC.-28.46%38 202
SEAGEN INC.-9.68%25 704
ICON PUBLIC LIMITED COMPANY-30.22%17 567